A three-year utilization analysis of branded second-generation antipsychotics at a regional health plan

Authors

Kamaladdin Saei, St. John Fisher UniversityFollow
Eddie Miljkovic, St. John Fisher University
Hailey Button, St. John Fisher UniversityFollow

Document Type

Poster Presentation

Publication Date

4-2025

Department

Pharmacy

Abstract

In the last 30 years,13 new antipsychotic entities have been approved by the Food and Drug Administration (FDA). Today, the majority of those are available generically.

Caplyta (lumateperone), Fanapt (Iloperidone), Rexulti (brexpiprazole), Vraylar (cariprazine), and the most recently approved, Lybalvi (olanzapine/samidorphan), continue to be available only as brand name products.

The cost of antipsychotics in 2023 was $18.04 billion USD.

It is anticipated that this market will continue to increase at about eight percent annually, reaching $37.40 billion by 2032

Comments

Poster presented at the AMCP 2025 Annual Meeting, March 31- April 3, 2025, Houston, Texas.

Publication Information

Saei, Kamaladdin; Miljkovic, Eddie; and Button, Hailey, "A three-year utilization analysis of branded second-generation antipsychotics at a regional health plan" (2025). Doctoral External Publications. Paper 117.
https://fisherpub.sjf.edu/doctoral_ext_pub/117

Please note that the Publication Information provides general citation information and may not be appropriate for your discipline. To receive help in creating a citation based on your discipline, please visit http://libguides.sjfc.edu/citations.